Abstract
Hypnotic use in obstructive sleep apnoea (OSA) is contraindicated due to safety concerns. Recent studies indicate that single-night hypnotic use worsens hypoxaemia in some and reduces OSA severity in others depending on differences in pathophysiology. However, longer clinical trial data are lacking. This study aimed to determine the effects of 1 month of zopiclone on OSA severity, sleepiness and alertness in patients with low–moderate respiratory arousal thresholds without major overnight hypoxaemia.
69名参与者用表格状导管完成了生理筛查之夜,以量化唤醒阈值。30名合格患者(呼吸暂停 - hypopnoea指数(AHI)22±11事件·H-1) then completed standard in-laboratory polysomnography (baseline) and returned for two additional overnight sleep studies (nights 1 and 30) after receiving either nightly zopiclone (7.5 mg) or placebo during a 1-month, double-blind, randomised, parallel trial (anzctridentifier ANZCTRN12613001106729).
The change in AHI from baseline to night 30 was not different between zopiclone相对placebo groups (−5.9±10.2相对−2.4±5.5 events·h-1; p=0.24). Similarly, hypoxaemia, next-day sleepiness and driving simulator performance were not different.
1month of zopiclone does not worsen OSA severity, sleepiness or alertness in selected patients without major overnight hypoxaemia. As the first study to assess the effect of a hypnotic on OSA severity and sleepiness beyond single-night studies, these findings provide important safety data and insight into OSA pathophysiology.
Abstract
1个月的夜间zopiclone不会恶化OSA的严重程度或低温唤醒阈值的症状http://ow.ly/9JD230khJpl
Footnotes
This article has supplementary material available fromwww.qdcxjkg.com
This study is registered atanzctrwith identifier number ANZCTRN12613001106729.
作者贡献:S.G。Carter和D.J.埃克特(Eckert)撰写了手稿,所有作者都为最终版本和数据解释做出了贡献。S.G. Carter,L.P。Fisher和C.M.Rollo收集并分析了数据。G. Cho,D.J。Stevens和A.L. D'Rozario协助了数据收集。D.J.Eckert和J.C. Carberry协助了数据收集和分析,并与R.R. Grunstein和D.K.合作麦肯齐负责研究概念和设计。
利益冲突:S.G. Carter报告了国家卫生和医学研究委员会(NHMRC; Grant 1042493)的赠款,以及NHMRC研究卓越中心(Grant 1060992)的Neurosleep,个人费用(研究生研究奖学金),来自NeuroSleep,Neurosleep,Neurosleep,在研究过程中,澳大利亚神经科学研究(NEURA)的NHMRC研究卓越和个人费用(补充奖学金);以及在提交工作之外的Ressleep兼职工作的个人费用。
利益冲突:J.C. Carberry报告了NHMRC(授予1042493)和NHMRC研究卓越中心(Grant 1060992)的Neurosleep的赠款。
Conflict of interest: G. Cho reports grants from the NHMRC (grant 1042493) and NeuroSleep, a NHMRC Centre for Research Excellence (grant 1060992), during the conduct of the study.
Conflict of interest: L.P. Fisher reports grants from the NHMRC (grant 1042493) and NeuroSleep, a NHMRC Centre for Research Excellence (grant 1060992), during the conduct of the study.
利益冲突:C.M.Rollo报告了NHMRC的NHMRC(赠款1042493)和NHMRC研究卓越研究中心(Grant 1060992)的赠款。
利益冲突:D.J。史蒂文斯(Stevens)报告了NHMRC的赠款(赠款1042493)和NHMRC研究卓越中心(Grant 1060992)的Neurosleep,在研究进行了研究。
Conflict of interest: R.R. Grunstein reports grants the NHMRC (grant 1042493) and NeuroSleep, a NHMRC Centre for Research Excellence (grant 1060992), during the conduct of the study, and personal fees for local advisory board activity from Merck and Teva, outside the submitted work.
利益冲突:D.J。Eckert reports grants from the NHMRC (grant 1042493 and fellowship 1116942) and NeuroSleep, a NHMRC Centre for Research Excellence (grant 1060992), during the conduct of the study, and grants from Commonwealth Government of Australia Cooperative Research Centre Grant (industry partner Oventus Medical) and personal fees for advisory board activities and consultancy from Bayer, outside the submitted work.
Conflict of interest: A.L. D'Rozario reports grants from the NHMRC (grant 1042493), and NeuroSleep, a NHMRC Centre for Research Excellence (grant 1060992), during the conduct of the study.
支持声明:这项研究由澳大利亚项目赠款(1042493)的国家健康与医学研究委员会(NHMRC)和NHMRC研究卓越中心Neurosleep(1060992)资助。D.J.ECKERT得到了NHMRC高级研究奖学金(1116942),R.R. Grunstein的支持,由NHMRC高级首席研究奖学金(1106974)和A.L. D'Rozario通过NHMRC-ARC研究奖学金(11077716)。本文的资金信息已存入CrossRef资助人注册表。
- Received2018年1月24日。
- 公认May 23, 2018.
- Copyright ©ERS 2018